NCT01403311View on ClinicalTrials.gov

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2015

Conditions
Glioma
Interventions
DRUG

5-Aminolevuline Acid

5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery

Trial Locations (1)

97210

Legacy Health System, Portland

Sponsors
All Listed Sponsors
collaborator

DUSA Pharmaceuticals, Inc.

INDUSTRY

lead

Legacy Health System

OTHER